Abstract
Emergence of drug resistance in Escherichia coli due to various mechanisms makes the treatment choices very limited. The objective of this research was to investigate extended-spectrum beta-lactamases (ESBLs) and AmpC lactamases in E. coli isolates from urinary tract infections (UTIs) and to assess their antibacterial susceptibility patterns in a health-care context. Atotal of 70 E. coli isolates from clinically assumed cases of UTI patients during the 9months period. The isolates with bacteriuria (105 CFU/ml) were identified. ESBL and AmpC were detected phenotypically. Out of the 70 isolates of uropathogenic E. coli, ESBL production was detected in 34(48.6%) isolates and AmpC producer in 27(38.6%) of isolates in which 14(20%) of them showed coexistence phenotype of both ESBLs and AmpC and 23(32.9%) E. coli isolates were both ESBL and AmpC non-producer. The findings donated information regarding drug resistance. The level of resistance recorded in ESBL-and AmpC-producing uropathogenic E. coli of this study was raising; therefore, it is crucial to have a strict infection control measures and routine monitoring of ESBL-and AmpC-producing bacteria in clinical laboratory.